Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, Sedona, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Vassall, Anna, Dodd, Matthew, Fielding, Katherine, Nyang’wa, Bern-Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022130/
https://www.ncbi.nlm.nih.gov/pubmed/36962909
http://dx.doi.org/10.1371/journal.pgph.0001337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022130/
https://www.ncbi.nlm.nih.gov/pubmed/36962909
http://dx.doi.org/10.1371/journal.pgph.0001337

Ejemplares similares